Ipratropium bromide nasal solution 0.06% is indicated for symptomatic relief of rhinorrhea associated with the common cold or ...

Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food ...

The root of the U.S.’s high prescription drug prices lies in its unique system, which allows pharmaceutical manufacturers to ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...

Harry Sumnall receives funding from public grant awarding bodies for alcohol and other drugs research, and fees from (international) not-for-profit organisations and government departments for ...

Only 78 were for tiotropium, while the remaining prescriptions were for ipratropium bromide alone by metered-dose inhaler (55%) or nebulization (7%), or ipratropium bromide in a fixed-dose ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, 46brooklyn Research, an Ohio non-profit focused on U.S. drug pricing data ...